Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Dr Brinda Sethugavalar studied primary medical education at the University of Dundee Medical School and obtained MBChB in 2004. She completed her specialist registrar training in Leeds Teaching Hospitals in 2015. Dr Brinda Sethugavalar obtained her fellowship at the Royal College of Radiology (RCR) in 2013. She specialises in breast cancer, lymphoma radiotherapy and non-melanoma skin cancers.
Proton Beam Therapy
This consultant has received training from the Rutherford Cancer Centres in the delivery of proton beam therapy. The programme, Proton Therapy Clinical Education, in conjunction with The Perelman School of Medicine at the University of Pennsylvania and IBA, the leading proton beam therapy solutions manufacturer, involves oncologists gaining practical experience in Penn’s Roberts Proton Therapy Center – one of the world’s leading centres of proton therapy research and expertise.
Fellowship of Royal College of Radiology (FRCR) - 2013
Membership of the Royal College of Physicians (MRCP)
Dr Brinda Sethugavalar's research interests include:
Royal College of Radiology (RCR) - a national audit on early and locally advanced breast cancer. Data collection of radiotherapy patients within the department has shown that results are in line with RCR recommendations.
FASTFORWARD study - Dr Brinda Sethugavalar is the PI for this study, it looks into Hypofractionated radiotherapy in breast cancer. She was involved in patient recruitment and contouring of individual cases.
IDRIS study - radiotherapy and lenolidomide in patients with solitary plasmacytoma. Dr Brinda Sethugavalar outlined the benchmark cases for national peer review. This is currently waiting for the trial to open for recruitment following QA (quality assuarance).
POSNOC - a trial on radiotherapy or surgery vs observation in low risk breast cancer. Dr Brinda Sethugavalar is involved in patient selection at MDT level.
IMPORT High - long term follow up and assessment of toxicity.
Dr Brinda Sethugavalar does not hold a share or financial interest in the Rutherford Cancer Centres or another Rutherford Health plc company.
Dr Brinda Sethugavalar does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Rutherford Health plc company.
Dr Brinda Sethugavalar does not hold any paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Rutherford Health plc.
Get in Touch
If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or
This page was printed directly from www.therutherford.com/consultants/dr-brinda-sethugavalar on 15 May 2021, 04:57pm and is correct at the time of printing. Please note: this website is updated periodically and information may be amended or deleted if required. Please refer back to the website to ensure the information is correct at the time of enquiry.